deferasirox has been researched along with Cardiomyopathies in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, JA; Tchantchaleishvili, V; Vidula, H | 1 |
| Allò, M; Cuccia, L; D'Ascola, DG; Gamberini, MR; Lisi, R; Mangione, M; Meloni, A; Pepe, A; Pistoia, L; Positano, V; Restaino, G; Ricchi, P; Righi, R; Rosso, R; Spasiano, A | 1 |
| Cappellini, MD; Castiglioni, C; Longo, F; Origa, R; Piga, A; Pinna, F; Roggero, S; Zappu, A | 1 |
| Agapidou, A; Boura, P; Klonizakis, P; Mavroudi, M; Spanos, G; Vetsiou, E; Vlachaki, E | 1 |
| Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Khamseekaew, J; Kumfu, S; Srichairatanakool, S; Sripetchwandee, J; Wongjaikam, S | 1 |
| Chang, JS; Chiou, SS; Hsiao, CC; Hung, GY; Peng, CT; Wang, LY; Wang, SC; Wu, KH | 1 |
| Coates, TD; Giardina, P; Glynos, T; Harmatz, P; Kang, BP; Paley, C; Thompson, A; Wood, JC | 1 |
| Aydinok, Y; Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, MS; Habr, D; Ibrahim, H; Kattamis, A; Li, CK; Pennell, DJ; Porter, JB; Roubert, B; Smith, G; Taher, A; Viprakasit, V | 1 |
| Cabantchik, ZI; Hershko, C; Konijn, AM; Link, G | 1 |
| Aguilar, M; Moats, R; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Berdoukas, V; Modell, B | 1 |
1 review(s) available for deferasirox and Cardiomyopathies
| Article | Year |
|---|---|
Objectives and mechanism of iron chelation therapy.
Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Mitochondria, Heart; Mononuclear Phagocyte System; Pyridones; Rats; Thalassemia; Transfusion Reaction; Triazoles | 2005 |
4 trial(s) available for deferasirox and Cardiomyopathies
| Article | Year |
|---|---|
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.
Topics: Adult; Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Female; Ferritins; Hemosiderosis; Humans; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Medication Adherence; Prospective Studies; Stroke Volume; Transfusion Reaction; Triazoles; Young Adult | 2014 |
Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Topics: Adult; Benzoates; beta-Thalassemia; Cardiomyopathies; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Function, Left; Young Adult | 2015 |
Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.
Topics: Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Liver Diseases; Siderosis; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles | 2010 |
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Chelation Therapy; Child; Deferasirox; Drug Administration Schedule; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Magnetic Resonance Angiography; Triazoles | 2012 |
6 other study(ies) available for deferasirox and Cardiomyopathies
| Article | Year |
|---|---|
Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy.
Topics: Adult; Cardiomyopathies; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Extracorporeal Membrane Oxygenation; Female; Hemochromatosis; Humans; Iron Chelating Agents; Shock, Cardiogenic | 2018 |
MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Substitution; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Prospective Studies; Treatment Outcome | 2018 |
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
Topics: Acetylcysteine; Animals; Benzoates; Cardiomyopathies; Cardiotonic Agents; Deferasirox; Deferiprone; Deferoxamine; Drug Combinations; Drug Synergism; Humans; Iron; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Malondialdehyde; Mitochondria; Pyridones; Rats; Rats, Wistar; Triazoles; Ventricular Function, Left | 2016 |
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic; Combined Modality Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Guidelines as Topic; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Pyridones; Siderophores; Siderosis; Taiwan; Treatment Outcome; Triazoles | 2009 |
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.
Topics: Animals; Benzoates; Cardiomyopathies; Deferasirox; Disease Models, Animal; Drug Administration Schedule; Female; Gerbillinae; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Triazoles | 2007 |
Transfusion-dependent thalassaemia: a new era.
Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte Transfusion; Ferritins; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Myocardium; Patient Compliance; Pyridones; Siderophores; Thalassemia; Triazoles | 2008 |